The Philippines' Chemical and Pharmaceutical Industries

As of 2026-09-08 · Updated 2026-09-08 · Section: Economy, Industry & Business · 日本語版

0. Summary — The 30-Second Version

1. Where the Industry Stands

The Philippine chemical industry has a structure, within ASEAN, that is extremely thin upstream (petrochemicals) and heavily weighted downstream (compounding, molding, consumer goods). While Singapore, Malaysia, Thailand, Indonesia, and Vietnam all maintain naphtha crackers or large integrated petrochemical complexes, the Philippines lost its only cracker in 2025.

注 Older Japanese-language reference material still describes the Philippines as "one of ASEAN's leading chemical producers," but upstream petrochemical output has been zero since 2025, and using that description without qualification is a factual error. Since rankings ("#X in ASEAN") vary widely depending on the metric used, this article does not state a ranking and treats it as unconfirmed.

On the policy side, the Board of Investments (BOI) oversees the Chemical Industry Roadmap and the Integrated Roadmap for the Philippine Pharmaceutical Industry, and is working on revisions together with the industry association SPIK (Samahan sa Pilipinas ng mga Industriyang Kimika, the Chemical Industries Association of the Philippines) (per BOI and SPIK published materials).

2. Petrochemicals — JG Summit's Withdrawal (2025)

2-1. What Happened

注注 (Detected in the 2026-08-25 verification pass. The 2025 profit figure on a continuing-operations basis differs between sources — both are presented here rather than deleting either)

Both the amount and the direction of the year-on-year change diverge — this is not simply a rounding difference. This likely reflects either (1) a difference in metric — "recurring/core" (adjusted for one-off items) versus "reported continuing-operations net income" — or (2) a transcription discrepancy on the reporting side. This survey could not reach JG Summit's own full-year 2025 disclosure (jgsummit.com.ph's press-release page has not been updated since May 2022, and the full-year 2025 release could not be located) = unconfirmed. 注 When citing this figure, always specify whether it is "recurring/core" or "as reported." By contrast, the ₱87.9 billion full-year 2025 net loss is consistent across both sources and may be treated as a settled figure. Note also that 1H2026 core net income was ₱13 billion (−37%) (per the conglomerates article), which reflects fuel-cost pressure on Cebu Pacific (separate from petrochemicals) plus interest expense inherited from the petrochemical unit at the parent-company level. Do not mix figures across fiscal periods.

2-2. Capacity Lost (Important)

注 The new 250,000-tonne PE line had only just come online in July–August 2024 and was shut down less than a year later. Any 2024-era claim that "the new capacity secures the future" is now entirely out of date.

2-3. Impact on Demand

According to Argus Media, 2024 domestic consumption in the Philippines was approximately 170,000 tonnes of LLDPE, 240,000 tonnes of HDPE, and 440,000 tonnes of PP. With JGSOC shut down, these volumes have in principle switched entirely to imports.

An industry survey (Kantor Materials, 13 April 2026) estimates the Philippines' resin-processing volume at 1.2–1.5 million tonnes/year, with an import share of 80–90% for polyolefins (PE/PP) and 60–75% across resins overall. It puts the remaining domestic producers — NPC Alliance, Petron, Philippine Resins Industries (PRII), and others — at a combined ~575,000 tonnes/year. This is an industry estimate, not an official government statistic.

The same report cites three reasons for 2026's import share being heavily skewed toward China: (1) ACFTA's zero tariff, (2) the September 2025 lapse of the HDPE safeguard tariff, and (3) an $80–150/tonne raw-material cost advantage over Korean suppliers (all industry-side claims that this survey could not independently verify against primary sources).

3. Refining — A "Single-Plant" Structure

3-1. Shell Tabangao's Conversion to an Import Terminal

(Source: Oil & Gas Journal, 2020)

3-2. Petron's Bataan Refinery

• The only refinery currently operating in the Philippines is Petron's Limay plant in Bataan, said to supply roughly a third of national fuel demand (source replaced 2026-08-27: the earlier draft cited the English-language Wikipedia article "Bataan Refinery" among other sources. Its stated capacity of roughly 180,000 barrels/day has not been confirmed against Petron's own primary sources = unconfirmed).
• It was temporarily idled from December 2020 into 2021 (Oil & Gas Journal), illustrating the structural weakness of the Philippines' fuel and petrochemical-feedstock supply: "there is only one refinery, and even that one can go idle."
• In June 2026, in response to shrinking jet-fuel buffers, the company applied to expand storage capacity at the Bataan terminal (Philstar, Manila Times, BusinessWorld, 10–11 June 2026).

3-3. Petron's Performance (Hit Directly by the 2026 Middle East Conflict)

Petron itself cites "Middle East geopolitical instability pushing up crude prices, import premiums, and shipping costs" as the cause. Dubai crude peaked at $129/barrel in March 2026, fell to $79 by June, averaged $86 in Q1 and $96 in Q2, for an H1 average of $91 (+27% year-on-year) (Petron press release).

注 The key point is that revenue rose 57% while profit fell. Because the Philippine oil and chemical sector swings on "price pass-through lag" and "inventory valuation," looking at revenue alone gives a misleading picture.

3-4. The 2026 Upheaval in Crude Sourcing

• In March 2026, the Philippines imported Russian crude for the first time in five years (about 2.48 million barrels). Petron locked in the purchase amid the Middle East conflict (Philstar, Manila Bulletin, Borneo Post, GMA, March 2026).
• 注 Initial reports in May said the crude was Iranian; this was later corrected to Russian (Baird Maritime, 9 June 2026). Reporting on 2026 crude sourcing has been inconsistent, and primary-source verification is needed.
• In late March 2026, Ramon Ang (RSA) renewed his proposal to sell Petron to the government (InsiderPH, Inquirer.net, Philstar), directly tied to the broader national fuel-security debate.

4. Fertilizer — Import Dependence and the 2026 Price Spike

4-1. Supply Structure

Per the Department of Agriculture (DA, da.gov.ph, 2026):

Agriculture Secretary Francisco Tiu Laurel Jr. said, "Supply is not the problem — price is," pointing to logistics costs and market uncertainty as the real issues.

4-2. Prices (Old vs. New, Side by Side)

Fertilizer and Pesticide Authority (FPA) weekly prices, WK32 (3–7 August 2026), national weighted average retail price per 50kg sack

As of April 2026 (DA data, BusinessMirror, 13 April 2026)

注 Prices have eased somewhat from April's peak (₱2,600) to August's ₱2,444, but remain well above the pre-conflict level of around ₱1,720. The "₱1,500–1,800/sack" figure commonly cited in Japanese-language material is from 2025 or earlier and no longer applies in 2026.

The DA has warned that under a worst-case scenario in which urea reaches ₱3,000/sack, palay (unmilled rice) production could fall from a projected 19.87 million tonnes to 17.63 million tonnes — a 10-year low (BusinessMirror, 13 April 2026). It also noted that diesel reaching ₱160/liter is undermining the economics of mechanized farming.

4-3. Moves Toward Domestic Production

• In March 2026, the Philippines held additional fertilizer-procurement talks with China (BusinessWorld, 17 March 2026).
• In April 2026, the DA was considering a ~$1 million feasibility study for a coal-based urea plant on Semirara Island (Daily Tribune, 21 April 2026). This remains at the conceptual stage; nothing has been decided.
• The House Committee on Policy and Budget Research Department (CPBRD) published discussion paper DP2026-17, "Seeds of a Food Crisis: Fertilizer Supply Disruptions in the Philippines Amidst the US-Iran Conflict" (May 2026). The full PDF could not be retrieved due to bot protection; its contents remain unconfirmed.

5. Other Chemicals — Oleochemicals as an "Exceptional Strength"

While upstream petrochemicals have disappeared, coconut-derived oleochemicals remain one of the few chemical segments where the Philippines has a raw-material advantage.

• D&L Industries (including Chemrez): 1H2025 net income of ₱1.4 billion (+6%), export sales of ₱7.4 billion (+18%, 38% of gross profit), with profit at the new Batangas plant tripling year-on-year to ₱597 million. CEO Alvin Lao noted that "coconut oil prices hit record highs, making Q2 tough" (D&L Industries press release, August 2025).
• 注 Oleochemicals face headwinds when coconut oil prices rise. Do not oversimplify the claim that "it's strong because the raw material is domestic."

Other downstream segments include chlor-alkali (Mabuhay Vinyl), PVC (Philippine Resins Industries), industrial gases, and compounding industries such as paints, adhesives, and detergents. This survey could not obtain the latest confirmed production volumes and market sizes for these from the PSA's (Philippine Statistics Authority) annual establishment survey (ASPBI); treated as unconfirmed.

6. The Pharmaceutical Market — Figures That Swing More Than Threefold Depending on Definition

6-1. 注注 Market-Size Figures Must Always Come With Their Definition

The same term, "the Philippine pharmaceutical market," varies more than fourfold — from $2.1 billion to $9.1 billion. The gap comes down to whether it is measured at wholesale or retail, prescription-only or including OTC/supplements, and domestic manufacturing only or including imports. Whenever you cite one, name the source, the year, and the definition. This survey could not determine which is "correct" — treated as unconfirmed.

6-2. Trade Balance and Import Dependence

BMI summarizes that the Philippines "depends almost entirely on imports for APIs, mostly from China and India," while "advanced biologics and specialty drugs are imported from the US and Europe, with domestic manufacturers concentrated on generics" (via BusinessMirror, 12 March 2026).

6-3. The Players

注 On retail market share, industry sources claiming "TGP is largest, with Mercury Drug second, and the two together holding over 60%" conflict with the more common understanding that "Mercury Drug is the largest." The share figures themselves could not be verified in this survey — unconfirmed. Unilab's "roughly $2 billion" in sales, likewise, comes from a corporate database rather than a primary source, since Unilab is unlisted — primary source unconfirmed.

(Added in the 2026-08-25 verification: the discrepancy is likely a difference in metric) - Both the "Conglomerates" article (§5) and the "Notable People — Economy and Culture" article (§2-8) describe Mercury Drug as "the largest domestic drugstore chain." Founded by Mariano Que in 1945; roughly 1,200 stores and over 15,000 employees. The owning Que Azcona family ranked 8th on Forbes Philippines' 2026 rich list, at $2.5 billion (source: Forbes profile "Vivian Que Azcona," source of wealth listed as drugstores; Vivian Que Azcona, the majority shareholder and president, died in April 2025 at age 69). - "TGP is largest" typically refers to store count (it leads through an aggressive franchise model), while "Mercury Drug is largest" typically refers to revenue. 注 Stating "the largest" without specifying the metric makes the two claims look contradictory when they may in fact be describing different rankings. - 注 That said, the underlying claims themselves — "TGP has the most stores" and "the two together hold over 60%" — could not be traced to a primary source in this review either = unconfirmed. Neither claim is discarded; whenever you state a ranking, specify whether it is store-count-based or revenue-based, and for what year. - 注 The claim "the Que Azcona family = Monde Nissin" is incorrect (Monde Nissin belongs to the Quifanes/Dalmono family). This mix-up has already been detected and corrected once within this document set ("Conglomerates," cross-check record #1).

7. Pharmaceutical Regulation — Three Pillars You Must Get Right

7-1. The Generics Act (RA 6675, Generics Act of 1988)

注 "A brand-name-only prescription is illegal" is often the first thing that trips up Japanese medical institutions and pharmaceutical firms operating in the Philippines.

7-2. The Cheaper Medicines Act (RA 9502, Universally Accessible Cheaper and Quality Medicines Act of 2008)

注注 (Corrected in the 2026-08-25 check. Source: RA 9502 text obtained directly from lawphil.net) The initial draft had listed "Section 93" and "Section 93-A" alongside Sections 17, 18, and 19 as if they were RA 9502's own section numbers — this was an error. Sections 93 and 93-A are in fact section numbers of the Intellectual Property Code (RA 8293); within RA 9502, it is Section 10 that amends Section 93, and Section 11 that creates Section 93-A. Citing the basis for compulsory licensing as "RA 9502, Section 93" would name a section that does not exist. The correct citation is "RA 8293, Section 93 (as amended by RA 9502, Section 10)." Section 7 alone was correctly noted in the original draft as amending Section 72.1 of the IP Code.

7-3. Maximum Drug Retail Price (MDRP/MRP)

(2026-08-25 verification) All items regarding the signing dates and molecule/formulation counts for EO 104 and EO 155 were re-checked in full against the original text on lawphil.net and matched the original draft exactly. No errors found. 注 However, the "120 molecules under EO 104 and EO 155 combined" figure in the summary (§0) refers to 86 + 34 = 120 (the molecules actually placed under price caps). The "122 molecules" mentioned in the body of EO 104 refers to the scope including the 36 additional molecules under review, not the number already regulated. 120 and 122 are distinct figures — do not conflate them.

• MRP (Maximum Retail Price): applies to all public and private retailers, including drugstores, hospitals/hospital pharmacies, HMOs, convenience stores, and supermarkets (EO 104).
• MWP (Maximum Wholesale Price): applies to manufacturers, wholesalers, traders, and distributors (EO 104).
• Labels must carry the red-band notice "RETAIL PRICE NOT TO EXCEED" and "UNDER DRUG PRICE REGULATION" (EO 155).
• A 90-day non-extendible grace period allows existing stock to be sold at prior prices upon implementation (EO 104, EO 155).
• Coverage and prices are to be reviewed 6 months after implementation and every 6 months thereafter (EO 104, EO 155).
• Violations are handled under RA 9502 and related laws; the Secretary of Health investigates and imposes administrative penalties (EO 155).

7-4. Price Freezes (RA 7581, Price Act)

Separate from the MDRP framework, a state-of-calamity declaration automatically triggers a price freeze in the affected area.

• July 2025: Following Typhoon Emong and tropical depressions Dante and Crising, a 60-day price freeze on 148 essential medicines was imposed in affected areas (DOH, OneNews.ph, 25 July 2025), covering anesthetics, analgesics, anti-asthmatics, anticoagulants, diabetes medicines, antidiarrheals, antidotes, antiemetics, antihistamines, antihypertensives, antibiotics, antipsychotics, disinfectants, cardiotonics, corticosteroids, diuretics, insulin, antifungals, vitamins/minerals, and more.
• Penalties for violations: 1–10 years imprisonment and a fine of ₱5,000–₱1 million (DTI).
• Under the 2026 national energy emergency, an automatic price freeze applies to medicines listed on the Philippine National Drug Formulary (PNDF), per DOH explanation (SunStar, 26 March 2026).

8. FDA Philippines and the Approval System

• The regulator is the Food and Drug Administration (FDA Philippines), under the Department of Health (DOH). Marketing a medicine requires an LTO (License to Operate) and a CPR (Certificate of Product Registration).
• AO 2024-0013 (effective 2025) comprehensively revised registration rules for human medicines and APIs, requiring submissions in ASEAN Common Technical Dossier (ACTD)/CTD format (per industry commentary; the FDA's own original text could not be retrieved, as fda.gov.ph returns an access refusal — unconfirmed).
• Review pathways are being organized into full/abridged/verification/reliance (deference to other regulatory authorities) tracks.
• GMP: domestic companies need domestic certification; importers need SRA (Stringent Regulatory Authority)/GMP certification.
• An e-CPR (electronic CPR) pilot is underway.
• PAC (Post-Approval Change) rules were finalized in October 2025.
• In January 2026, the FDA introduced a "Green Lane" program, which the PCPI has voiced support for. It offers eligible domestic manufacturers of essential medicines faster review timelines, clearer documentation requirements, and closer coordination with the regulator. PCPI Chairman Balajadia said the initiative "draws on proven models from Singapore, India, and China" (BusinessWorld, 26 January 2026).

注 The reality of review timelines: BMI notes that "the target is 254 days, but in practice it can take 2 to 4 years" (via BusinessMirror, 12 March 2026). Do not take the 254-day figure at face value.

9. Import Dependence and Localization Policy

• The BOI's Integrated Roadmap for the Philippine Pharmaceutical Industry sets a goal of manufacturing 60% of registered medicines domestically (per USAID PQM+-related reporting).
• Tuberculosis (TB) and HIV medicines are named as priority areas, given large demand, limited domestic manufacturing capacity, and high global-supply-chain vulnerability (same source).
• PQM+ (Promoting the Quality of Medicines Plus) is a USAID-supported program launched in 2019. This survey could not confirm the effect, if any, of post-2025 changes in US foreign-aid policy on this program.
• Key figures: BOI Executive Director Ma. Corazon Halili-Dichosa; FDA's Engr. Maria Cecilia Matienzo; PPMA Chairman Engr. Higinio Porte Jr.; USAID's Dr. Yolanda Oliveros.

10. Vaccines — The Push for Domestic Production (As of 2026)

10-1. RA 12290 (Virology and Vaccine Institute of the Philippines Act)

(Source: RA 12290 text on lawphil.net)

10-2. Progress

注注 There is currently no fact of "the Philippines producing vaccines domestically." RA 12290 is a legal framework for R&D infrastructure; the facility is still under construction, and the IRR only entered the drafting stage in 2026. Any claim of "Philippine-made vaccines starting in 2026" is incorrect.

注 Change of Health Secretary: Teodoro ("Ted") Herbosa resigned on 13 July 2026, and Dr. Jose Brittanio "Brix" Pujalte Jr., former head of the Philippine Orthopedic Center, was appointed and sworn in on 15 July (Rappler, Manila Bulletin, Philstar). DOH statements before April 2026 are Herbosa's; those from July onward are Pujalte's — take care when citing which.

11. Impact of the 2026 Middle East Conflict (From 28 February)

11-1. The Macro Timeline

(Source replaced 2026-08-27: the earlier draft had aggregated various reports via the English-language Wikipedia article. Replacement with individual primary reporting was not completed in this session = requires re-verification. Only some items have been confirmed against primary sources)

注 The figure "the Philippines imports 98% of its oil from the Middle East" has circulated in connection with March 2026 government announcements, but the original PCO statement could not be retrieved even in this verification pass, so the single figure of 98% is unconfirmed. (Added in the 2026-08-25 check) However, within this document set, the "Oil, Natural Gas, and Undersea Resources" article, §14, states Middle East dependence for oil as a range of "95–98%." Citing a range of "95–98%" rather than a single figure is the most defensible position this document set currently supports.

11-2. Impact on the Chemical Industry

• Petrochemicals: Since JGSOC was already shut down, there was no direct impact on operations. However, since the industry had just switched to full import reliance on resins right before freight rates spiked, processors' procurement costs deteriorated on two fronts at once.
• Fertilizer: As noted above, urea prices are up roughly 50%. The DA, while framing it as "a price problem, not a supply problem," projects upward pressure on food prices of ₱2–5 per kilogram, and is promoting substitution with bio-fertilizer (priced at ₱750/kg, described as equivalent to two 50kg sacks of urea).
• Fuel costs: Diesel at around ₱160/L (April 2026) hit chemical plants' logistics and utility costs directly.
• 注注 (Time-stamped in the 2026-08-25 check. This was "the peak level in April," not the current value) Per the confirmed series in the "Electricity and Power Rates" article, §4, Metro Manila diesel went from about ₱55/L just before the war began (late February 2026) → ₱130–140/L in March (Philstar reported a peak of ₱170/L) → ₱85.50/L as of 17 August 2026 (GlobalPetrolPrices; ₱53.10/L a year earlier = +61%). The correct figure for August 2026 is that diesel remains elevated in the ₱85–90/L range. Using "₱160" as the assumption for late-2026 costs would overstate them. That said, Energy Secretary Garin has stated plainly that "even after the conflict ends, prices will not return to the pre-war ₱50–60/L level," so assuming a return to pre-war levels is also mistaken.

11-3. Impact on the Pharmaceutical Industry (This Is the Core Topic Here)

PHAP's 10-point proposal (10 April 2026, context.ph)

Citing a 12–24 month production lead time for medicines — meaning "today's supply disruption becomes tomorrow's shortage months later" — PHAP called on the government to:

1. Secure a 6-month national inventory buffer
2. Establish joint public-private demand forecasting
3. Create a National Medicines Logistics Command Center (real-time monitoring)
4. Establish green lanes at ports (priority customs clearance for pharmaceutical cargo)
5. Expand cold-chain storage capacity
6. Grant priority fuel allocation for medicine distribution
7. Pursue cross-sector pooled procurement
8. Apply flexible regulation and time-limited tax incentives
9. Exempt medicines from VAT to offset logistics costs
10. Strengthen public-private cooperation under the UHC Law framework

12. Key Points for Japanese Companies and Practitioners

13. Main Sources (Primary Materials and Originals)

• Statutory text on lawphil.net: RA 6675 (13 September 1988), RA 9502 (6 June 2008), RA 12290 (12 September 2025), EO 104 (17 February 2020), EO 155 (7 December 2021)
• Fertilizer and Pesticide Authority (FPA), Weekly Fertilizer Prices WK32-2026 (3–7 August 2026): https://fpa.da.gov.ph/weekly-prices/
• Department of Agriculture (DA): https://www.da.gov.ph/da-assures-fertilizer-supply-eyes-alternatives-amid-tensions/
• Petron Corporation press releases (4 August 2026 H1 results, 3 March 2026 full-year 2025 results): https://www.petron.com/news/
• Oil & Gas Journal (Shell Tabangao closure, 2020): https://www.ogj.com/
• Argus Media (JG Summit petrochemical shutdown, January 2025)/MRC, Chemical Week (March 2025)
• OneNews.ph (JG Summit sale talks, 26 March 2026)
• BusinessWorld (26 January 2026 FDA Green Lane; 6 April 2026 pharmaceutical cost/supply issues)
• BusinessMirror (12 March 2026 BMI forecast; 13 April 2026 urea prices; 1 February 2026 VIP)
• ABS-CBN (10 April 2026 DOH medicine prices)/SunStar (26 March 2026 DOH/WHO)/OneNews.ph (25 July 2025 148-item price freeze)
• context.ph (10 April 2026 PHAP 10-point proposal)/GMA Network (31 July 2026 VIP and self-reliance)
• Congressional Policy and Budget Research Department (CPBRD) DP2026-17 (May 2026, full text not obtained)

日本語の詳細版: 分野「経済・産業・ビジネス」「化学・医薬品産業」（本サイト日本語版）。